CPSE:COLO BMedical Equipment
Coloplast (CPSE:COLO B) Valuation Check After Solid Q1 Earnings And Confirmed Growth Guidance
Coloplast (CPSE:COLO B) is back in focus after reporting first quarter results that showed organic revenue and EBIT growth, while also confirming guidance for around 7% EBIT growth in constant currencies for 2025-2026.
See our latest analysis for Coloplast.
Despite the solid Q1 update and confirmed guidance, sentiment around Coloplast has been weak. The 30 day share price return of 12.34% and 1 year total shareholder return of 34.73% are both firmly negative, pointing to fading momentum...